SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-215607
Filing Date
2022-08-09
Accepted
2022-08-09 07:31:01
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d359961d8k.htm   iXBRL 8-K 25516
2 EX-99.1 d359961dex991.htm EX-99.1 60869
6 GRAPHIC g359961g35q56.gif GRAPHIC 2844
  Complete submission text file 0001193125-22-215607.txt   226408

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fusn-20220809.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20220809_lab.xml EX-101.LAB 18689
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20220809_pre.xml EX-101.PRE 11694
8 EXTRACTED XBRL INSTANCE DOCUMENT d359961d8k_htm.xml XML 3517
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 221146410
SIC: 2836 Biological Products, (No Diagnostic Substances)